ORIGINAL ARTICLE


Acesso aberto Revisado por pares

5533

Visualizações

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil

Luciana R. da Silva1, Cid M.M. Vianna1, Gabriela B.G. Mosegui2, Antônio A.F. Peregrino3, Valeska Marinho4, Jerson Laks4,5

Vol.41 Issue 3/2019: 218-224

ABSTRACT

OBJECTIVE: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer's disease (AD) from the perspective of the Brazilian Unified Health System.
METHOD: A hypothetical cohort of 1,000 individuals of both sexes, aged >65 years, and diagnosed with AD was simulated using a Markov model. The time horizon was 10 years, with 1-year cycles. A deterministic and probabilistic sensitivity analysis was performed.
RESULTS: For mild AD, the study showed an increase in quality-adjusted life years (QALYs) of 0.61 QALY/21,907.38 Brazilian reais (BRL) for patients treated with donepezil and 0.58 qAlY/BRL 24,683.33 for patients treated with rivastigmine. In the moderate AD group, QALY increases of 0.05/BRL 27,414.96 were observed for patients treated with donepezil and 0.06/BRL 34,222.96 for patients treated with rivastigmine.
CONCLUSIONS: The findings of this study contradict the standard of care for mild and moderate AD in Brazil, which is based on rivastigmine. A pharmacological treatment option based on current Brazilian clinical practice guidelines for AD suggests that rivastigmine is less cost-effective (0.39 QALY/BRL 32,685.77) than donepezil. Probabilistic analysis indicates that donepezil is the most cost-effective treatment for mild and moderate AD.

Keywords: Alzheimer's disease; economic issues; administration; geriatric psychiatry


THE CONTENT OF THIS ARTICLE IS NOT AVAILABLE FOR THIS LANGUAGE.


© 2026 All rights reserved